Sunny Sun

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.

C. Diazgranados, M. R. Capeding, G. Dayan, 2020, The Lancet. Infectious diseases.

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials

L. Shek, N. H. Tran, Chan Quang Luong, 2019, Human vaccines & immunotherapeutics.